Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, 1200 Bruxelles, Belgium.
Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, 1200 Bruxelles, Belgium.
Trends Mol Med. 2019 Oct;25(10):882-896. doi: 10.1016/j.molmed.2019.04.009. Epub 2019 May 31.
Interfering with endocannabinoid (eCB) metabolism to increase their levels is a proven anti-nociception strategy. However, because the eCB and prostanoid systems are intertwined, interfering with eCB metabolism will affect the prostanoid system and inversely. Key to this connection is the production of the cyclooxygenase (COX) substrate arachidonic acid upon eCB hydrolysis as well as the ability of COX to metabolize the eCBs anandamide (AEA) and 2-arachidonoylglycerol (2-AG) into prostaglandin-ethanolamides (PG-EA) and prostaglandin-glycerol esters (PG-G), respectively. Recent studies shed light on the role of PG-Gs and PG-EAs in nociception and inflammation. Here, we discuss the role of these complex systems in nociception and new opportunities to alleviate pain by interacting with them.
干扰内源性大麻素 (eCB) 代谢以增加其水平是一种经过验证的抗伤害感受策略。然而，由于 eCB 和前列腺素系统相互交织，干扰 eCB 代谢会影响前列腺素系统，反之亦然。这种联系的关键是 eCB 水解时产生环氧化酶 (COX) 底物花生四烯酸，以及 COX 将 eCBs 大麻素 (AEA) 和 2-花生四烯酸甘油 (2-AG) 代谢为前列腺素-乙醇胺 (PG-EA) 和前列腺素-甘油酯 (PG-G) 的能力。最近的研究揭示了 PG-G 和 PG-EA 在伤害感受和炎症中的作用。在这里，我们讨论了这些复杂系统在伤害感受中的作用，以及通过与它们相互作用来缓解疼痛的新机会。
